Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma

Giovanni L. Ceresoli, Paolo A. Zucali, Fabio De Vincenzo, Letizia Gianoncelli, Matteo Simonelli, Elena Lorenzi, Cristina Ripa, Laura Giordano, Armando Santoro

Research output: Contribution to journalArticlepeer-review

Abstract

The role of second-line therapy in patients with malignant pleural mesothelioma (MPM) progressing after first-line pemetrexed-based chemotherapy (PBC) is currently undefined. Recent case series have suggested a possible role of re-treatment with PBC. In this observational study, the activity and safety of this therapeutic option was assessed in a consecutive series of cases. Patients with complete response (CR), partial response (PR) or stable disease (SD) lasting for at least 3 months after first-line PBC were retreated with PBC, either as second-line (2L) or further-line (>2L) therapy. Descriptive analyses of progression-free survival (PFS), overall survival (OS), response rate and toxicity are reported. Between October 2004 and July 2009, 31 patients (21 males and 10 females) received re-treatment with PBC as 2L (18 patients) or beyond 2L therapy (13 patients). Median age was 65 years (range 37-81). Fifteen patients were re-treated with pemetrexed alone, and 16 with a pemetrexed/platinum combination. An objective response was achieved in 6 patients (one CR and 5 PRs), for a response rate of 19%. Nine patients (29%) had SD after treatment. Overall, the disease control rate (DCR) was 48%. Median PFS and overall survival (OS) after re-treatment with PBC were 3.8 months and 10.5 months, respectively. PFS and OS after re-treatment with PBC were correlated with PFS achieved after first-line PBC (FL-PFS). Patients with a FL-PFS >12 months had a median PFS after re-treatment of 5.5 months, while patients with a FL-PFS ≤12 months had a median PFS after re-treatment of 2.5 months; no patient in this group was progression-free at 1 year. Toxicity was mild, with grade 3 or 4 hematological toxicity occurring in 9.7% of patients. In conclusion, re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (>12 months) disease control with first-line PBC. Further prospective evaluation of this therapeutic option is warranted.

Original languageEnglish
Pages (from-to)73-77
Number of pages5
JournalLung Cancer
Volume72
Issue number1
DOIs
Publication statusPublished - Apr 2011

Keywords

  • Disease control
  • Malignant pleural mesothelioma
  • Pemetrexed
  • Progression-free survival
  • Re-treatment
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this